Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Amicus Therapeutics (FOLD) Deferred Taxes (2016 - 2023)

Amicus Therapeutics filings provide 3 years of Deferred Taxes readings, the most recent being -$4.9 million for Q1 2023.

On a quarterly basis, Deferred Taxes changed N/A to -$4.9 million in Q1 2023 year-over-year; TTM through Dec 2023 was -$4.9 million, a 54977.78% decrease, with the full-year FY2023 number at -$4.9 million, down 54977.78% from a year prior.
Deferred Taxes hit -$4.9 million in Q1 2023 for Amicus Therapeutics, down from $9000.0 in the prior quarter.
In the past five years, Deferred Taxes ranged from a high of $9000.0 in Q4 2022 to a low of -$4.9 million in Q1 2023.